Woburn, Massachusetts-based Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has raised $62 million in Series C financing. Perceptive Advisors led the round.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: